Logo of plosoneLink to Publisher's site
PMC full text:

Table 4

Secondary Performance Endpoint Improvements in Stage 1.
RintatolimodPlacebo
Secondary Performance EndpointBaselineWeek 40p-value1 BaselineWeek 40p-value1
Karnofsky Performance Score (KPS)5055<0.015050<0.01
Activities of Daily Living (ADL)68.172.4<0.0168.769.4ns2
Vitality Score (SF-36)5.010.0<0.0110.010.0ns2
General Health Perception (SF-36)2020ns2 2025<0.01
1p-value derived from a Wilcoxon signed rank test comparing whether the median change from Baseline is equal to 0 within each treatment group.
2ns = not significant, p>0.05.